Clinical Trials Logo

Drug Resistant Epilepsy clinical trials

View clinical trials related to Drug Resistant Epilepsy.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03196934 No longer available - Refractory Epilepsy Clinical Trials

Expanded Use of Cannabidiol Oral Solution

Start date: n/a
Phase:
Study type: Expanded Access

To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.

NCT ID: NCT03014440 No longer available - Clinical trials for Drug Resistant Epilepsy

Study of Cannabidiol for Drug-Resistant Epilepsies

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. Pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. There are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. There are no well-documented studies and completely analyzed data for pediatric epileptic patients.

NCT ID: NCT02461706 No longer available - Epilepsy Clinical Trials

Treatment of Drug Resistant Epilepsy

Cannabidiol
Start date: n/a
Phase:
Study type: Expanded Access

The main goal of this study is to provide treatment with cannabidiol (CBD) to children with drug resistant epilepsy through a Physician Expanded Access Investigation New Drug protocol. As the controlled therapeutic use of CBD in children is novel, the primary objective of this study is to evaluate the safety and efficacy of CBD when administered as adjunctive therapy in children that have exhausted the majority of FDA approved antiepileptic drug treatment options.